The effects of beta-adrenoreceptor blockade on oxygen consumption during cardiopulmonary bypass

Impact of a β-blocker and/or acute hemodilution on cerebral oxygenation during apneic hypoxia

BACKGROUND

β-blockers reduce the tolerance for acute hemodilution by decreasing cerebral oxygenation and may contribute to the incidence of stroke. We hypothesized that β-blockers also increase the risk for cerebral hypoxia when apneic hypoxia occurs.

METHODS

After induction of isoflurane, 14 swine (mean ± SD =25.3 ± 0.8 kg) were studied using 200 μg/kg/min of landiolol or saline (control group) in three sequential stages: before, during, and after landiolol (saline) infusion. In each stage, after 5 min of mechanical ventilation with 100% oxygen, apnea was induced until the time to < 70% oxygen saturation. Hemodynamic and blood gas variables were measured, and the cerebral tissue oxygenation index (TOI) was recorded by near infrared spectroscopy (apnea experiment). After these steps, hemodilution was induced by hemorrhage of 600 ml and infusion of the same volume of hydroxyethylstarch, and the apnea experiments were then conducted before, during, and after landiolol (saline) infusion similarly to before hemodilution.

RESULTS

Landiolol decreased TOI at 1 min after apnea and at SpO2 < 70% by 3.3% and 7.0% from each corresponding value at baseline, and by 13.1% and 20.3% during hemodilution. Landiolol shifted the relationship between TOI and arterial hemoglobin oxygen saturation (SaO2 ) or arterial partial pressure of oxygen (PaO2 ) to the left; and reduced TOI at similar arterial blood oxygenation. This phenomenon was marked during hemodilution.

CONCLUSIONS

Landiolol reduces cerebral tissue oxygenation during apneic hypoxia. β-blockers increase the risk for cerebral hypoxia when apneic hypoxia occurs, especially during acute hemodilution.

Acute ischemic syndromes following coronary artery bypass graft surgery

Coronary artery bypass graft (CABG) surgery, performed for the control of angina pectoris, leads to postoperative relief from symptoms in most patients. Amelioration of ischemia and improvement in exercise capacity after CABG are well documented. However, patients currently undergoing CABG are more complex than in the past--they are older and are maintained on medical therapy for longer periods. A large number of these patients have had one or more previous myocardial revascularization procedures. The post-operative period would appear to be a time of vulnerability for coronary events. However, previous investigators have focused on the pre- and intraoperative aspects of peri-CABG ischemia. Outcome data suggest that the postoperative interval is at least equally important as a determinant of short- and long-term morbidity and mortality. We discuss the epidemiology, etiology, pathophysiology, and treatment of ischemic syndromes in the postoperative period after CABG. In addition, we review recent data from a series of 14 patients, observed at our institution, who underwent cardiac catheterization and, in some cases, angioplasty of the culprit vessel in the immediate postoperative period.

Temporary biventricular pacing postcardiopulmonary bypass in patients with reduced ejection fraction

BACKGROUND AND AIM

Patients with low ejection fraction (EF) undergoing myocardial revascularization frequently require ventricular pacing following cardiopulmonary bypass (CPB). While the benefits of chronic biventricular (BiV) pacing in patients with low EF are well established, there are little data on acute effects during heart surgery. This study analyzed the response of BiV versus single ventricle lead pacing on hemodynamics and left ventricular (LV) function immediately following CPB.

METHODS

Ten patients with decreased LV EF (mean = 35 +/- 6%) underwent open-heart surgery with CPB. Temporary pacing electrodes were placed on the right atrium, apex of the right ventricle, and lateral wall of the LV after separation from CPB. The hemodynamic effects of three atrio-ventricular (right, left, and BiV) pacing modes were studied for four minutes each. The pacing sequence was randomly allocated with a resting period of three minutes between each mode. Hemodynamic and echocardiographic data of LV function were collected. Statistical analysis was performed with analysis of variance.

RESULTS

BiV pacing increased cardiac output by 4%, 13%, and 44% over right ventricular pacing, LV pacing, and pre-bypass values, respectively. The fractional area of change increased significantly with BiV pacing compared to right ventricular and LV pacing (36%, 35% to 44%, p < 0.01). An increased propagation velocity of 49 cm/s compared to 38 cm/s and 40 cm/s for right ventricular and LV pacing, respectively, suggested an improvement in diastolic function.

CONCLUSION

In patients with low EF, BiV pacing immediately after CPB significantly improves LV systolic function and cardiac output, and suggests significantly improved diastolic function.

Modulation of beta-adrenergic receptor subtype activities in perioperative medicine: mechanisms and sites of action

This review focuses on the mechanisms and sites of action underlying beta-adrenergic antagonism in perioperative medicine. A large body of knowledge has recently emerged from basic and clinical research concerning the mechanisms of the life-saving effects of beta-adrenergic antagonists (beta-AAs) in high-risk cardiac patients. This article re-emphasizes the mechanisms underlying beta-adrenergic antagonism and also illuminates novel rationales behind the use of perioperative beta-AAs from a biological point of view. Particularly, it delineates new concepts of beta-adrenergic signal transduction emerging from transgenic animal models. The role of the different characteristics of various beta-AAs is discussed, and evidence will be presented for the selection of one specific agent over another on the basis of individual drug profiles in defined clinical situations. The salutary effects of beta-AAs on the cardiovascular system will be described at the cellular and molecular levels. Beta-AAs exhibit many effects beyond a reduction in heart rate, which are less known by perioperative physicians but equally desirable in the perioperative care of high-risk cardiac patients. These include effects on core components of an anaesthetic regimen, such as analgesia, hypnosis, and memory function. Despite overwhelming evidence of benefit, beta-AAs are currently under-utilized in the perioperative period because of concerns of potential adverse effects and toxicity. The effects of acute administration of beta-AAs on cardiac function in the compromised patient and strategies to counteract potential adverse effects will be discussed in detail. This may help to overcome barriers to the initiation of perioperative treatment with beta-AAs in a larger number of high-risk cardiac patients undergoing surgery.

[Perioperative beta-blockers. Part two: therapeutic indications]

PURPOSE

To review the pharmacologic and pathophysiologic information necessary to prescribe beta-blockers (BB) in perioperative medicine.

DATA SOURCE

Manual retrieval and electronic research of the literature using MEDLINE (key-words: anesthesia and beta- blocker; surgery and beta-blocker).

DATA SYNTHESIS

In non cardiac surgery, the beneficial effects of BB have been demonstrated in hypertensive patients since 1979. In 1996, the beneficial effects of atenolol in patients with coronary artery disease (reduction of postoperative myocardial ischemia and overall reduction in two-year mortality) were demonstrated. In coronary surgery, the interest of preoperative BB treatment has been shown since 1983. Administration of BB has been shown to be beneficial in acute myocardial infarction or chronic cardiac failure (except in NYHA class IV patients).

CONCLUSION

BB have been shown to exert a beneficial effect on postoperative outcomes in patients with cardiovascular disease or risk factors, and their more widespread use in perioperative medicine is encouraged.